Last reviewed · How we verify
NCT07172867
A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM
Phase 2 trial testing HT-6184 in Diabetes Mellitus, Type 2. Withdrawn.
23 January 2026
Quick facts
| Lead sponsor | Halia Therapeutics, Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Start date | 6 January 2026 |
| Primary completion | 23 January 2026 |
| Estimated completion | 23 January 2026 |
| Sites | 1 location across United Arab Emirates |
Drugs / interventions tested
- HT-6184 — full drug profile →
- HT-6184 Matching Placebo — full drug profile →
- Semaglutide 1 mg
Conditions studied
- Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →
- Obesity — all drugs for Obesity →
Sponsor
Halia Therapeutics, Inc. — full company profile →
Who can join
Adults 18 to 65, any sex, with Diabetes Mellitus, Type 2 or Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the efficacy and safety of ofirnoflast in combination with semaglutide in comparison to semaglutide alone in obese participants with T2DM.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
NLRP3 inhibition by VTX3232 tempers inflammation resulting in reduced body weight, hyperglycemia, and hepatic steatosis in obese male mice.
Bultinck J, Yuan S, Cantuti-Castelvetri L, Brosens L, et al · · 2026 · PMID 41242536 · DOI 10.1016/j.molmet.2025.102282
Verify or expand the search:
- PubMed search for NCT07172867
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of HT-6184
Trials testing the same drug.
- NCT06241742 — Evaluating Ability of HT-6184 to Reduce Inflammation and Pain After Third Molar Extraction · Phase 2 · completed
- NCT07052006 — A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia · Phase 2 · active not recruiting
- NCT05447546 — Study to Evaluate HT-6184 in Healthy Subjects · Phase 1 · completed
Other recruiting trials for Diabetes Mellitus, Type 2
Currently open trials in the same condition.
- NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
- NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
- NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
- NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
- NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
Other Halia Therapeutics, Inc. trials
Trials by the same sponsor.
- NCT07399171 — Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers · Phase 2 · not yet recruiting
- NCT06537817 — Study to Evaluate HT-4253 in Healthy Subjects · Phase 1 · completed
- NCT06241742 — Evaluating Ability of HT-6184 to Reduce Inflammation and Pain After Third Molar Extraction · Phase 2 · completed
- NCT07052006 — A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia · Phase 2 · active not recruiting
- NCT05447546 — Study to Evaluate HT-6184 in Healthy Subjects · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07172867 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Halia Therapeutics, Inc.
- Last refreshed: 25 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07172867.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing